These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1913467)

  • 1. An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression.
    Barosi G; Buratti A; Costa A; Liberato LN; Balduini C; Cazzola M; Rosti V; Magrini U; Ascari E
    Cancer; 1991 Nov; 68(10):2310-8. PubMed ID: 1913467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Portal or hepatic vein thrombosis as the first presentation of a myeloproliferative disorder in patients with normal peripheral blood counts.
    McNamara C; Juneja S; Wolf M; Grigg A
    Clin Lab Haematol; 2002 Aug; 24(4):239-42. PubMed ID: 12181028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematological causes of venous thrombosis in young people: high incidence of myeloproliferative disorder as underlying disease in patients with splanchnic venous thrombosis.
    Teofili L; De Stefano V; Leone G; Micalizzi P; Iovino MS; Alfano G; Bizzi B
    Thromb Haemost; 1992 Mar; 67(3):297-301. PubMed ID: 1641818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.
    De Stefano V; Teofili L; Leone G; Michiels JJ
    Semin Thromb Hemost; 1997; 23(5):411-8. PubMed ID: 9387199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis--possible evidence of an occult myeloproliferative state.
    Pagliuca A; Mufti GJ; Janossa-Tahernia M; Eridani S; Westwood NB; Thumpston J; Sawyer B; Sturgess R; Williams R
    Q J Med; 1990 Sep; 76(281):981-9. PubMed ID: 2236481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Portal vein thrombosis following splenectomy for hematologic disease: prospective study with Doppler color flow imaging.
    Chaffanjon PC; Brichon PY; Ranchoup Y; Gressin R; Sotto JJ
    World J Surg; 1998 Oct; 22(10):1082-6. PubMed ID: 9747171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic and hemorrhagic complications in chronic myeloproliferative disorders.
    Sagripanti A; Ferretti A; Nicolini A; Carpi A
    Biomed Pharmacother; 1996; 50(8):376-82. PubMed ID: 8952859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies.
    Manoharan A; Gemmell R; Brighton T; Dunkley S; Lopez K; Kyle P
    Br J Haematol; 1999 Jun; 105(3):618-25. PubMed ID: 10354122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms.
    Gugliotta L; Iurlo A; Gugliotta G; Tieghi A; Specchia G; Gaidano G; Scalzulli PR; Rumi E; Dragani A; Martinelli V; Santoro C; Randi ML; Tagariello G; Candoni A; Cattaneo D; Ricco A; Palmieri R; Liberati MA; Langella M; Rago A; Bergamaschi M; Monari P; Miglio R; Santoro U; Cacciola R; Rupoli S; Mastrullo L; Musto P; Mazzucconi MG; Vignetti M; Cortelezzi A; Vianelli N; Martino B; De Stefano V; Passamonti F; Vannucchi AM;
    Leuk Res; 2016 Jul; 46():18-25. PubMed ID: 27107744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
    Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
    Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome.
    Valla D; Casadevall N; Lacombe C; Varet B; Goldwasser E; Franco D; Maillard JN; Pariente EA; Leporrier M; Rueff B
    Ann Intern Med; 1985 Sep; 103(3):329-34. PubMed ID: 4026081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased levels of the soluble adhesion molecule E-selectin in patients with chronic myeloproliferative disorders and thromboembolic complications.
    Musolino C; Alonci A; Allegra A; Spatari G; Bellomo G; Tringali O; Quartarone C; Squadrito G; Quartarone M
    Am J Hematol; 1998 Feb; 57(2):109-12. PubMed ID: 9462541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
    Michiels JJ; Juvonen E
    Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive value of megakaryocytic and erythroid colony formation and platelet function tests on the risk of thromboembolic and bleeding complications in essential thrombocythaemia.
    Niittyvuopio R; Juvonen E; Kekomäki R; Oksanen K; Anttila P; Ruutu T
    Eur J Haematol; 2004 Apr; 72(4):245-51. PubMed ID: 15089761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of erythroid progenitors to recombinant growth factors in the diagnosis of myeloproliferative disorders.
    Dudley JM; Westwood N; Woodcock S; Pearson TC; Eridani S
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():199-202. PubMed ID: 2324555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
    Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis.
    Chait Y; Condat B; Cazals-Hatem D; Rufat P; Atmani S; Chaoui D; Guilmin F; Kiladjian JJ; Plessier A; Denninger MH; Casadevall N; Valla D; Brière JB
    Br J Haematol; 2005 May; 129(4):553-60. PubMed ID: 15877740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Platelet function in chronic myeloproliferative syndromes associated with thrombocytosis].
    Grebe G; Pereira J; Mezzano D; Legues ME; Aranda E; Lira P
    Rev Med Chil; 1985 Jan; 113(1):32-7. PubMed ID: 4081383
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential thrombocythemia. Clinical characteristics and course of 61 cases.
    Hehlmann R; Jahn M; Baumann B; Köpcke W
    Cancer; 1988 Jun; 61(12):2487-96. PubMed ID: 3365670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.